BOSTON - Tango Therapeutics Inc. (NASDAQ:TNGX) announced initial results from its Phase 1/2 trial evaluating vopimetostat combined with RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma, according to a press release statement issued today.
The trial enrolled 59 patients with previously treated pancreatic cancer or non-small cell lung cancer as of May 28, 2026. Patients received vopimetostat, an investigational PRMT5 inhibitor, combined with either daraxonrasib or zoldonrasib.
In the vopimetostat plus daraxonrasib arm, 12 pancreatic cancer patients were response evaluable with at least 14 weeks of follow-up. The combination showed a 92% objective response rate, with 11 of 12 patients responding and 9 responses confirmed. The 6-month progression-free survival rate was 90%, and disease control rate reached 100%. Among three evaluable non-small cell lung cancer patients, all three achieved confirmed responses.
The vopimetostat plus zoldonrasib combination in 27 evaluable pancreatic cancer patients demonstrated a 52% objective response rate, with 10 of 14 responses confirmed, a 74% 6-month progression-free survival rate, and 96% disease control rate.Investors have responded enthusiastically to the trial data, with Tango’s stock delivering a 375% return over the past year, bringing its market capitalization to $2.9 billion. The shares currently trade at $20.22, though InvestingPro analysis suggests the stock is overvalued relative to its Fair Value estimate.
Both combinations were generally well-tolerated. Most adverse events were Grade 1 or 2, with no related Grade 4 or 5 adverse events reported. Common treatment-related adverse events included rash, stomatitis, mucositis, diarrhea, nausea, and vomiting. Three dose-limiting toxicities occurred in two patients at the higher vopimetostat dose level with daraxonrasib.
Tango plans to advance the vopimetostat plus daraxonrasib combination into Phase 3 development for first-line MTAP-deleted pancreatic cancer, subject to regulatory feedback. The company expects to finalize the Phase 3 trial design in the second half of 2026.
MTAP deletions occur in approximately 40% of pancreatic cancers and 15% of lung cancers. For deeper insights into Tango’s financial health and access to exclusive ProTips, visit InvestingPro.
In other recent news, Tango Therapeutics has seen significant developments across various fronts. The company recently reported its first-quarter 2026 earnings, revealing a potential shift in strategy by prioritizing a RAS combination approach for treating pancreatic ductal adenocarcinoma. Piper Sandler responded to this strategic shift by downgrading Tango Therapeutics to Neutral from Overweight, while still raising the price target to $24.00. Meanwhile, Mizuho increased its price target for the company to $30, maintaining an Outperform rating, based on the progress in the company’s first-line pancreatic ductal adenocarcinoma program.
Jefferies also downgraded Tango Therapeutics to Hold from Buy, raising the price target to $27.00 and highlighting the company’s ongoing development of PRMT5 and RAS combination treatments. Stifel expressed increased confidence in the potential of Tango Therapeutics’ drug combination, raising its price target to $40 while maintaining a Buy rating. Additionally, Tango Therapeutics finalized a separation agreement with its former CFO, Daniella Beckman, following her departure from the company. These developments reflect a dynamic period for Tango Therapeutics as it continues to advance its therapeutic programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for TNGX plus thousands of other stocks and find your next hidden gem with massive upside.